Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Johnson

Showing results (141-150 of 284) with videos related to

Pageof 29
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Phase II study of imatinib in patients with small cell lung cancerBruce E Johnson, Thomas Fischer, Berthold Fischer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation ConsortiumRobin Guo, Lynne D Berry, Dara L Aisner, et al.
Academic Radiology|November 2, 2010
CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical toolMizuki Nishino, Mengye Guo, David M Jackman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trialsDavid M Jackman, Vincent A Miller, Leigh-Anne Cioffredi, et al.
Future Oncology (London, England)|December 17, 2021
Encorafenib plus binimetinib in patients with <i>BRAF</i><sup>V600</sup>-mutant non-small cell lung cancer: phase II PHAROS study designGregory J Riely, Myung-Ju Ahn, Enriqueta Felip, et al.
HGG Advances|June 21, 2024
Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancerXinan Wang, Kangcheng Hou, Biagio Ricciuti, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 22, 2009
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective studyTamara R Tilleman, William G Richards, Lambros Zellos, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2014
Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancerRavi B Parikh, Angel M Cronin, David E Kozono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
Integration of molecular profiling into the lung cancer clinicWilliam Pao, Mark G Kris, A John Iafrate, et al.
Lung Cancer (Amsterdam, Netherlands)|September 24, 2022
Safety of image guided research biopsies in patients with thoracic malignanciesSteffan K Soosman, Matthew P Schenker, Emanuele Mazzola, et al.
Pageof 29

Showing results (141-150 of 284) with videos related to

Sort By:
Pageof 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Phase II study of imatinib in patients with small cell lung cancerBruce E Johnson, Thomas Fischer, Berthold Fischer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation ConsortiumRobin Guo, Lynne D Berry, Dara L Aisner, et al.
Academic Radiology|November 2, 2010
CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical toolMizuki Nishino, Mengye Guo, David M Jackman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trialsDavid M Jackman, Vincent A Miller, Leigh-Anne Cioffredi, et al.
Future Oncology (London, England)|December 17, 2021
Encorafenib plus binimetinib in patients with <i>BRAF</i><sup>V600</sup>-mutant non-small cell lung cancer: phase II PHAROS study designGregory J Riely, Myung-Ju Ahn, Enriqueta Felip, et al.
HGG Advances|June 21, 2024
Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancerXinan Wang, Kangcheng Hou, Biagio Ricciuti, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 22, 2009
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective studyTamara R Tilleman, William G Richards, Lambros Zellos, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2014
Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancerRavi B Parikh, Angel M Cronin, David E Kozono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
Integration of molecular profiling into the lung cancer clinicWilliam Pao, Mark G Kris, A John Iafrate, et al.
Lung Cancer (Amsterdam, Netherlands)|September 24, 2022
Safety of image guided research biopsies in patients with thoracic malignanciesSteffan K Soosman, Matthew P Schenker, Emanuele Mazzola, et al.
Pageof 29